Metozolv Odt Patent Expiration

Metozolv Odt is a drug owned by Salix Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 11, 2017. Details of Metozolv Odt's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6413549 Fast-Dispersing solid oral dosage form containing coarse particles
Jul, 2017

(7 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Metozolv Odt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Metozolv Odt's family patents as well as insights into ongoing legal events on those patents.

Metozolv Odt's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Metozolv Odt's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 11, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Metozolv Odt Generics:

Metoclopramide Hydrochloride is the generic name for the brand Metozolv Odt. 38 different companies have already filed for the generic of Metozolv Odt, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Metozolv Odt's generic

How can I launch a generic of Metozolv Odt before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Metozolv Odt's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Metozolv Odt's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Metozolv Odt -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
5 mg and 10 mg 24 Aug, 2010 1 15 Aug, 2014 11 Jul, 2017 Extinguished Deferred

Alternative Brands for Metozolv Odt

Metozolv Odt which is used for multiple sclerosis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriasis., has several other brand drugs using the same active ingredient (Metoclopramide Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Evoke Pharma Inc
Gimoti
Meda Pharms
Reglan Odt


Apart from brand drugs containing the same ingredient, some generics have also been filed for Metoclopramide Hydrochloride, Metozolv Odt's active ingredient. Check the complete list of approved generic manufacturers for Metozolv Odt





About Metozolv Odt

Metozolv Odt is a drug owned by Salix Pharmaceuticals Inc. It is used for multiple sclerosis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriasis. Metozolv Odt uses Metoclopramide Hydrochloride as an active ingredient. Metozolv Odt was launched by Salix Pharms in 2009.

Approval Date:

Metozolv Odt was approved by FDA for market use on 04 September, 2009.

Active Ingredient:

Metozolv Odt uses Metoclopramide Hydrochloride as the active ingredient. Check out other Drugs and Companies using Metoclopramide Hydrochloride ingredient

Treatment:

Metozolv Odt is used for multiple sclerosis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriasis.

Dosage:

Metozolv Odt is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, ORALLY DISINTEGRATING Discontinued ORAL
EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, ORALLY DISINTEGRATING Discontinued ORAL